Tilak Mandadi Sells 69,551 Shares of CVS Health (NYSE:CVS) Stock

CVS Health Corporation (NYSE:CVS) EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. The trade was a 87.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

CVS Health Stock Up 3.2%

CVS Health stock opened at $95.19 on Wednesday. The company has a market capitalization of $121.45 billion, a P/E ratio of 41.93, a P/E/G ratio of 0.90 and a beta of 0.60. The firm’s fifty day simple moving average is $77.74 and its 200-day simple moving average is $78.24. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. CVS Health Corporation has a 1-year low of $58.35 and a 1-year high of $95.36.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. During the same quarter last year, the firm earned $2.25 EPS. CVS Health’s revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Sell-side analysts forecast that CVS Health Corporation will post 7.46 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were issued a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 2.8%. The ex-dividend date was Thursday, April 23rd. CVS Health’s dividend payout ratio (DPR) is 117.18%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. JPMorgan Chase & Co. lifted their price target on CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a research report on Tuesday. Truist Financial lifted their price target on CVS Health from $98.00 to $102.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. HSBC boosted their price objective on CVS Health from $83.00 to $85.00 and gave the company a “hold” rating in a research report on Tuesday, May 5th. Piper Sandler lowered their price target on CVS Health from $101.00 to $99.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 31st. Finally, DA Davidson increased their price target on shares of CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.00.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: JPMorgan and Sanford C. Bernstein both raised their price targets on CVS and kept bullish ratings, signaling confidence that the stock still has room to run after its strong Q1 results. JPMorgan and Bernstein price target updates
• Positive Sentiment: TD Cowen also lifted its target and reiterated a buy rating, adding to the recent analyst optimism around CVS Health’s earnings momentum and raised full-year guidance. TD Cowen adjusts price target on CVS Health to 110 from 105
• Positive Sentiment: Recent commentary says CVS is still cheap relative to its improving earnings, revenue growth, and margins, with Q1 showing better profitability and management raising 2026 guidance. CVS Health: Still Cheap And Signs Of Improvement
• Positive Sentiment: CVS is also benefiting from business updates that favor lower-cost biosimilars in its commercial formularies, which could support cost control and improve competitiveness in pharmacy benefits. CVS Health Corporation Updates its Commercial Formularies
• Neutral Sentiment: The company disclosed insider selling by EVP Tilak Mandadi, who sold 69,551 shares. The size is notable, but it does not necessarily indicate a change in the company’s outlook. SEC Form 4 filing
• Neutral Sentiment: Additional articles and market chatter continue to highlight CVS as a value and dividend name, reinforcing the bullish tone but not adding a major new catalyst. CVS Health is a Top-Ranked Growth Stock

Hedge Funds Weigh In On CVS Health

Hedge funds and other institutional investors have recently made changes to their positions in the company. National Pension Service lifted its position in CVS Health by 3.1% in the 3rd quarter. National Pension Service now owns 3,999,622 shares of the pharmacy operator’s stock valued at $301,532,000 after acquiring an additional 119,189 shares in the last quarter. Kingsview Wealth Management LLC lifted its position in CVS Health by 316.2% in the 3rd quarter. Kingsview Wealth Management LLC now owns 104,432 shares of the pharmacy operator’s stock valued at $7,873,000 after acquiring an additional 79,340 shares in the last quarter. AE Wealth Management LLC lifted its stake in CVS Health by 6.2% in the 3rd quarter. AE Wealth Management LLC now owns 257,204 shares of the pharmacy operator’s stock valued at $19,391,000 after acquiring an additional 14,983 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in CVS Health by 11.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 225,116 shares of the pharmacy operator’s stock valued at $16,971,000 after acquiring an additional 22,653 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in CVS Health by 186.6% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 396,368 shares of the pharmacy operator’s stock valued at $30,568,000 after acquiring an additional 258,050 shares in the last quarter. 80.66% of the stock is owned by institutional investors.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.